Latest Market Entry News

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

EVE Health Group has completed manufacturing and distribution setup for Libbo™, its innovative oral dissolving film for erectile dysfunction, paving the way for near-term patient access via telehealth and pharmacy channels.

Iondrive Limited has marked a pivotal shift from development to commercialisation of its IONSolv™ technology, securing $4 million to target the US e-waste market and commissioning its pilot plant to refine critical minerals.

Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.

NuEnergy Gas Limited has completed drilling four wells at its Tanjung Enim project, gearing up for initial gas sales in the first half of FY26. The company also inked key agreements to finance and expand its coal bed methane operations in Indonesia.

Bass Oil Limited reported a 7.9% rise in quarterly oil sales revenue and a 7.4% increase in production, alongside a pivotal gas sales agreement with Origin Energy for the Vanessa gas field, pending regulatory approval.

First Graphene and UK manufacturer FP McCann have successfully produced the first batch of graphene-enhanced concrete roof tiles, marking a significant step toward low-carbon, high-performance construction materials in the UK housing sector.

De.mem Limited has reported its strongest December quarter yet, with record cash receipts and a positive operating cash flow for the full year, underpinned by recurring revenues and strategic expansion into the gold mining sector.

Cleo Diagnostics has broadened its U.S. market opportunity to around 2 million women annually and is on track to complete its pivotal clinical trial early this year, supported by a $5 million capital raise and regulatory progress.

Lotus Resources has made significant progress resolving sulphuric acid supply issues critical to ramping up production at its Kayelekera Uranium Mine, though full steady-state output is now expected in the second quarter of 2026.

Vitrafy Life Sciences has marked significant progress in Q2 FY2026 with a strategic partnership, commercial launch in North America, and advancing clinical trials, underpinning its growth in cryopreservation technology.

X2M Connect Limited reported a robust second quarter for FY26, with revenues climbing 65% and a notable narrowing of EBITDA losses, driven by strategic expansions in South Korea, Japan, and beyond.